Transurethral bipolar plasmakinetic resection of prostate for treatment of benign prostatic hyperplasia:a report of 526 cases

Objective To assess the efficacy and safety of transurethral bipolar plasmakinetic resection of prostate(TUPKRP) for the treatment of benign prostatic hyperplasia(BPH).Methods To summarize the data of 526 cases of benign prostatic hyperplasia(BPH) with obstructive symptom treated by TUPKRP.Results The duration of the procedure was 17-13(50.2±31.7)min,and resected tissue weighed 12-150(26.3±23.2)g;the intraoperative blood loss was 23-240(75.5±32.8)mL and no blood transfusion was required.Seven cases had perforation of prostatic capsule,no transurethral resection syndrome occurred.The peak urinary flow rate(Qmax) increased from(7.8±2.9)mL/s preoperatively to(19.4±1.4)mL/s 3 months postoperatively.The residual urine(RU) decreased from(90.8±30.7)mL preoperatively to(16.5±12.0)mL.The international prostate symptom score(IPSS) decreased from(24.5±4.5) preoperatively to(4.7±3.4).The scores of quality of life(QOL) decreased from(5.7±2.1) preoperatively to(1.5±0.4).Conclusion Transurethral bipolar plasmakinetic resection of prostate for the treatment of benign prostatic hyperplasia is effective and safe with few complications and lower expense,and is worth promoting.